Literature DB >> 25471015

Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.

Gagan Fervaha1, Ofer Agid2, Hiroyoshi Takeuchi3, Jimmy Lee3, George Foussias2, Konstantine K Zakzanis4, Ariel Graff-Guerrero2, Gary Remington2.   

Abstract

BACKGROUND: Movement disorders are common in individuals with schizophrenia, even in those who are not exposed to antipsychotic medications. Extrapyramidal symptoms (EPS) are among the most common abnormal movements in schizophrenia, but their relationship with other features of the illness such as cognition is not well characterized.
METHODS: Three hundred and twenty-five individuals with schizophrenia who were not receiving any antipsychotic or anticholinergic medication and participated in the baseline visit of the Clinical Antipsychotic Treatment of Intervention Effectiveness study were included in the present study. EPSs were assessed using the Simpson-Angus Scale, while cognition was measured with a comprehensive neuropsychological test battery. The relationship between EPS and cognitive test performance was evaluated both dimensionally and categorically.
RESULTS: Greater severity of EPS was significantly associated with worse cognitive test performance evaluated using a composite score. Eighty-six patients were identified as having parkinsonism and these patients performed worse on cognitive tests than non-parkinsonian patients. These findings remained significant even after accounting for other variables such as severity of psychopathology, sedation, akathisia and dyskinesia.
CONCLUSIONS: The present results demonstrate that severity of EPS is reliably linked with poorer scores on tests of cognition. While this may reflect a common pathophysiology underlying neuromotor and neurocognitive deficits, it may also be the case that parkinsonian symptoms such as rigidity and bradykinesia impede test taking ability. Regardless of mechanism, inferences regarding cognitive impairment should take into account the presence of EPS, as well as other variables that may mediate cognitive test findings.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Motor symptoms; Neurocognition; Parkinsonism; Psychomotor slowing; Psychotic disorder; Side effects

Mesh:

Year:  2014        PMID: 25471015     DOI: 10.1016/j.schres.2014.11.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

2.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

3.  [Schizophrenia and bipolar disorder : Treatment of cognitive impairments].

Authors:  P Riedel; M N Smolka; M Bauer
Journal:  Nervenarzt       Date:  2018-07       Impact factor: 1.214

4.  Prediction of Neurocognitive Deficits by Parkinsonian Motor Impairment in Schizophrenia: A Study in Neuroleptic-Naïve Subjects, Unaffected First-Degree Relatives and Healthy Controls From an Indigenous Population.

Authors:  Juan L Molina; Gabriela González Alemán; Néstor Florenzano; Eduardo Padilla; María Calvó; Gonzalo Guerrero; Danielle Kamis; Lee Stratton; Juan Toranzo; Beatriz Molina Rangeon; Helena Hernández Cuervo; Mercedes Bourdieu; Manuel Sedó; Sergio Strejilevich; Claude Robert Cloninger; Javier I Escobar; Gabriel A de Erausquin
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

5.  Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Authors:  Fernanda F Peres; Raquel Levin; Mayra A Suiama; Mariana C Diana; Douglas A Gouvêa; Valéria Almeida; Camila M Santos; Lisandro Lungato; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; D'Almeida Vânia; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

6.  Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia.

Authors:  Juan L Molina; María Calvó; Eduardo Padilla; Mara Balda; Gabriela González Alemán; Néstor V Florenzano; Gonzalo Guerrero; Danielle Kamis; Beatriz Molina Rangeon; Mercedes Bourdieu; Sergio A Strejilevich; Horacio A Conesa; Javier I Escobar; Igor Zwir; C Robert Cloninger; Gabriel A de Erausquin
Journal:  NPJ Schizophr       Date:  2017-01-11

7.  Age-Related Parkinsonian Signs in Microdeletion 22q11.2.

Authors:  Erik Boot; Thierry Q Mentzel; Lisa D Palmer; Peter N van Harten; Connie Marras; Anthony E Lang; Anne S Bassett
Journal:  Mov Disord       Date:  2020-05-09       Impact factor: 10.338

8.  Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents.

Authors:  Paulina Cieślik; Monika Woźniak; Jerri M Rook; Mohammed N Tantawy; P Jeffrey Conn; Francine Acher; Krzysztof Tokarski; Magdalena Kusek; Andrzej Pilc; Joanna M Wierońska
Journal:  Psychopharmacology (Berl)       Date:  2018-07-27       Impact factor: 4.530

9.  Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study.

Authors:  Stephan T Egger; Julio Bobes; Katrin Rauen; Erich Seifritz; Stefan Vetter; Daniel Schuepbach
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

10.  Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis.

Authors:  Steffen Moritz; Teresa Thoering; Simone Kühn; Bastian Willenborg; Stefan Westermann; Matthias Nagel
Journal:  Front Psychol       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.